NewSquare Capital’s Emergent Biosolutions EBS Stock Holding History

NewSquare Capital’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-37	Closed	-$236	–	475
2025 Q2	$236	Buy	+37	New	+$212	﹤0.01%	1225
2024 Q2	–	Sell	-63	Closed	-$159	–	381
2024 Q1	$159	Hold	63	–	–	﹤0.01%	407
2023 Q4	$151	Sell	63 -32	-34%	-$75	﹤0.01%	463
2023 Q3	$323	Hold	95	–	–	﹤0.01%	540
2023 Q2	$698	Sell	95 -17	-15%	-$158	﹤0.01%	648
2023 Q1	$1.16K	Buy	+112	New	+$1.35K	﹤0.01%	635

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

OHA

Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

NewSquare Capital's EBS Position: Q3 2025 in Review

NewSquare Capital sold out of Emergent Biosolutions (EBS) in Q3 2025, closing a stake of 37 shares — an estimated $236 sold.

NewSquare Capital first reported a position in EBS in Q1 2023 and held it in 6 quarters. The position peaked at $1.16K in Q1 2023. 169 funds tracked by Wall St. Rank hold EBS as of Q3 2025.

NewSquare Capital reported no remaining Emergent Biosolutions position as of Q3 2025 after selling out during the quarter.
NewSquare Capital sold 37 Emergent Biosolutions shares in Q3 2025, an estimated $236.
NewSquare Capital first reported a position in Emergent Biosolutions in Q1 2023 and held it in 6 quarters.
NewSquare Capital's Emergent Biosolutions position peaked at $1.16K in Q1 2023.
169 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2025.

Based on NewSquare Capital's 13F filing for Q3 2025, filed 12 Nov 2025.